Rick Simpson Oil (RSO) in Pickens County, Alabama: The Complete Guide by OilWell Cannabis

If you’re reading this in Pickens County, Alabama—whether you’re in Aliceville, Carrollton, Gordo, Reform, or out in the rural stretches between communities—you’ve probably heard whispers about Rick Simpson Oil. Maybe a neighbor mentioned it at the Friday night football game. Maybe you saw it discussed in an online forum for cancer caregivers. Maybe you’re one of the many hardworking folks across Pickens County who’ve been let down by conventional medicine and are searching for honest answers about what this “RSO” thing actually is, whether it works, and if it’s even legal here in West Alabama.

We at OilWell Cannabis understand that landscape. We know that Pickens County faces real healthcare challenges—limited specialist access, long drives to Birmingham or Tuscaloosa for oncology appointments, and a prescription opioid crisis that has touched nearly every family. We know that when the medical system fails you, the instinct to find alternatives becomes not just rational but necessary. That’s why we’ve created this comprehensive resource specifically for Pickens County residents: to give you the full, unfiltered truth about RSO, grounded in actual science, backed by our own journey from desperation to discovery, and delivered with the transparency that your community deserves.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

This experience resonates deeply across Pickens County. Whether you’re a construction worker who took a fall in Reform, a timber worker injured in the forests near Gordo, or anyone who has sat in a Carrollton clinic only to be handed another prescription that doesn’t work, you understand the frustration Simpson felt. The medical system in rural Alabama, like in small-town Canada, often leaves patients feeling dismissed when they ask about cannabis as an option.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed .

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others .

This free-distribution model is morally profound and directly connects to how we at OilWell approach our own open-source philosophy. Pickens County residents know the value of community support—it’s what makes rural Alabama strong. When someone is sick, neighbors bring casseroles, help with chores, and share what they have. Simpson’s model was the ultimate expression of that community ethic applied to medicine.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine .

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005 and again in 2009. He was charged with cannabis cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe .

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. The following is a detailed breakdown of the protocol as Simpson described it .

Goal: Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule:

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day. Total daily intake: approximately 30 to 45 milligrams. Simpson emphasized that initial doses should be very small to allow the body to adjust to THC’s psychoactive effects.
• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually. By the end of this period, the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, until the full 60 grams have been consumed.

Administration methods:

• Primary method—oral: Place the dose directly under the tongue (sublingual) or swallow it.
• Secondary method—topical: For skin cancers and external lesions, apply oil directly, cover with a bandage, and change every three to four days.
• Not recommended as primary—inhalation: Simpson acknowledged inhalation for immediate symptom relief but maintained that oral route was necessary for sustained, high-dose exposure.

Tolerance and psychoactive effects:

• Simpson maintained that patients would develop significant tolerance to THC’s psychoactive effects within approximately three to four weeks.
• He considered euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing.
• He recommended taking initial doses at night and avoiding driving or operating machinery during titration.

Post-protocol maintenance: After completing the 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.

Dietary and lifestyle recommendations: Simpson also advocated for dietary changes including reducing sugar intake and avoiding processed foods, though this advice was secondary and general.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials evaluating this specific 60-gram/90-day protocol for any cancer type or other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil per day. Assuming 60-90% THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, anxiety, panic, tachycardia, hypotension, and cannabis use disorder [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications but by his method and materials .

Source material: Simpson used high-THC, indica-dominant cannabis strains. There was no strain standardization—the starting material varied by availability and growing season.

Extraction solvent: Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid—or 99% isopropyl alcohol. Neither is a food-grade solvent, which is a significant safety issue.

Extraction process:

1. Dry cannabis placed in bucket
2. Covered with solvent and agitated
3. Solvent poured off through filter
4. Process repeated with fresh solvent
5. Combined solvent washes placed in rice cooker
6. Solvent evaporated at relatively low heat
7. Thick, dark oil remains
8. Transferred to oral syringes

Appearance and physical characteristics: Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil with a strong cannabis odor and possible solvent-residual smell.

Cannabinoid profile: Primarily decarboxylated delta-9 THC (60-90% estimated), with naturally occurring minor cannabinoids at uncontrolled ratios. No lab verification.

Terpene content: Minimal to none. The combination of solvent extraction and high-heat evaporation meant traditional RSO was effectively stripped of terpene content.

Standardization and testing: None. Every batch was different. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual solvent risk: Naphtha may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves potentially harmful residues in the finished oil.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions .

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally.

What the preclinical literature shows

• In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced results supporting cancer-cure claims .

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects but does not endorse cannabis or cannabis oil as a cancer treatment .
• The FDA has not approved any cannabis plant product for cancer treatment. Only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol/nabilone) have specific approvals [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH identifies the strongest cannabinoid evidence for rare epilepsies, chemotherapy-related nausea, and HIV/AIDS appetite—not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research when most of the world was ignoring it. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence then and is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in alternative-medicine literature.

The legacy of Rick Simpson and the evolution of modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that commercialization contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies .

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas we offer.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

Our formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content. We include live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level [20]-[28].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. Our sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoids across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg).

• Product format innovation. Simpson envisioned only one format: oral oil from a syringe. We offer both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging different pharmacokinetic profiles [14].

Solvent safety and extraction evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging leaves potentially harmful residues.

Modern cannabis extraction uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods.

This evolution connects directly to product-quality considerations that matter for Pickens County residents. When you’re buying any cannabis product—whether from a dispensary in Birmingham or ordering online—you deserve to know it’s free from harmful residues.

The decarboxylation question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent converted essentially all THCa into delta-9 THC. This meant patients had no choice about psychoactivity—the oil was always psychoactive.

Our sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by THCa evidence showing potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism—all without psychoactive effects [12].

Terpene loss in traditional RSO

Terpenes are volatile compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157°C. The traditional RSO production process destroyed terpenes through solvent extraction and high-heat evaporation.

Our formulas specify live terpenes at 5% with a defined seven-terpene profile. Each terpene has its own evidence profile discussed below. The entourage-effect literature provides the theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically [20][29].

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. His evidence was anecdotal, his production unstandardized, his claims untested.

This document takes a fundamentally different approach. We apply a formal evidence hierarchy: human clinical evidence first, then systematic reviews, then institutional summaries, then preclinical literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

We honor the historical origin of RSO while committing to the standards of modern cannabinoid science.

Simpson’s protocol vs. modern dosing considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between his dosing and dosing with our modern, standardized, multi-cannabinoid formulation is not straightforward.

Key differences:

• Cannabinoid concentration: Our sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60-90% delta-9 THC. Our formula distributes 16,590 mg across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg).
• Delta-9 THC exposure: Simpson’s protocol delivered approximately 600-900 mg of delta-9 THC per day. Our sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL).

Future dosing guidance for our products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in this document and by responsible titration principles.

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities. Reynosa is an industrial hub plagued by violence and cartel activity.

Colin’s childhood was marked by exposure to both opportunities and challenges. Early on, he learned to hustle, taking on risky work transporting items across the border. Those experiences exposed him to complexities and dangers. A lot of his best friends have been killed or are in prison. He has faced every form of violence imaginable. By sixteen, he had to leave home for good.

Despite the dangers, Colin did not fall into darker paths like selling harder substances. Instead, he focused on cannabis, seeing it as a safer alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned to creating a legal, legitimate business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines our approach.

Bentley’s story—the real beginning

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered a devastating verdict: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD—through a question that changed everything.

A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. He had never explored therapeutic applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered the impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond just getting high. It became a mission to create real solutions that alleviate pain and suffering, not just for pets but for people.

Colin’s personal battle—PTSD, benzo addiction, and Peace Gummies

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, we also offer Peace Gummies in vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Over time, the therapeutic benefits of cannabis that Colin first discovered through Bentley became the core of our work. We’ve developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

Media recognition across Texas and beyond

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Our foundational philosophy, captured in Colin’s first ABC13 feature in September 2019, remains our guiding principle: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Current operations and commitment to quality

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed.

Our products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset, but our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

For Pickens County residents, this means when you order from us, you’re not getting a faceless corporate product. You’re getting something made with the same care and precision that saved Bentley’s life and helped Colin reclaim his own life from PTSD and benzo addiction.

The OilWell RSO philosophy

Our RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define our approach:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. For Pickens County residents, this means you don’t need to qualify under Alabama’s restrictive medical cannabis program (TCUP) to access our products. You simply need to be 21+.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. This flexibility is crucial for Pickens County residents who may need daytime functionality for work, driving, or caregiving, but want full therapeutic strength at night.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford our products can source ingredients and make their own version. For Pickens County’s DIY community and those facing economic hardship, this ensures access isn’t limited by price.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what the science actually says. We distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill compliance and the THCa legal framework for Alabama

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in Alabama.

THCa—the key to Alabama accessibility: THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

For Pickens County residents, this means you can legally purchase, possess, and transport our products, then activate them through heating in the privacy of your home. The same product functions as non-psychoactive anti-inflammatory (used raw) OR full-potency psychoactive cannabinoid medicine (after decarboxylation).

Important legal notice for Alabama customers: While our products are federally legal and ship to Alabama, you accept responsibility for understanding and complying with local laws. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Open-source formulas—why we publish everything

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage. If you cannot afford our products—$129.99 for sublingual oil, $49.99 for vape cartridge—you can see exactly what the formula contains, source the individual cannabinoid distillates, and make your own version.

This is a direct echo of Rick Simpson’s original ethos. He gave his oil away and taught people how to make it. He never patented his method. We’ve adapted that ethos for the modern cannabinoid marketplace.

Bentley’s CBD golden paste recipe—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size and needs; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and black pepper. Stir until thoroughly mixed.
3. Cool and store in jar with lid. Refrigerate up to two weeks.
4. Add small amount of CBD oil to paste before giving to pet, adjusting dosage based on weight and health needs. Start low and increase gradually.

Serving suggestion: Mix small amount with pet’s food once or twice daily. Monitor for changes and consult veterinarian if concerns arise.

This recipe—published years before our RSO formulas—demonstrates that open-source is our foundational behavior, not a marketing strategy. For Pickens County pet owners facing similar crises, this information is freely available.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated. Our sublingual formula contains 1,500 mg of THCa in its acidic, non-psychoactive form, creating three distinct usage options:

Option 1—Raw, no heat: All 1,500 mg stays as THCa—completely non-psychoactive. This provides anti-inflammatory cannabinoid exposure without impairment, compatible with work, driving, and daytime use.

Option 2—Fully activated, home decarboxylation: Heat oil at 260°F (125°C) for 45-60 minutes. This converts 1,500 mg THCa into approximately 1,315 mg delta-9 THC, yielding ~1,405 mg total delta-9 THC when combined with existing 90 mg. You may also decarboxylate only a portion, preserving remainder in raw form.

Option 3—Vape, auto-decarboxylation: Our vape cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. This is the fastest-onset RSO delivery method.

The conversion chemistry: 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule.

Solvent-free production

Our RSO is not a traditional extraction product. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid that facilitates cannabinoid absorption through sublingual tissue and provides neutral taste—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

The broader OilWell product portfolio

Beyond RSO, we produce a range of cannabinoid products:

Asshole Peach—our most popular product. A carefully formulated experience providing euphoric, long-lasting sensation, particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive.

Peace Gummies—developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Also available in vape form for quick relief—Colin personally uses it to manage his insomnia and severe PTSD.

Custom creations—we offer custom-made products tailored to individual needs, including specific cannabinoid ratios, delivery formats, or formulations for unique health circumstances (vegans, diabetics, specific dietary needs).

Two product formats

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise 0.1 mL increments
• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Approximately 40-60 doses per bottle

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Six cannabinoids: CBD, CBG, delta-8 THC, THCa, CBN, CBC (delta-9 THC auto-decarbs during vaping)
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest delivery)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability/discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	0.1 mL increments
Daytime non-psychoactive	Sublingual (raw)	THCa stays inactive
Nighttime psychoactive	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive comparison—OilWell RSO vs. alternatives

OilWell RSO vs. Alabama medical cannabis (TCUP) dispensary RSO

Dimension	Alabama TCUP RSO	OilWell RSO
Cannabinoid profile	THC-only (~420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible)	0 mg	1,500 mg (~1,315 mg delta-9 THC when decarbed)
Total cannabinoids	~420 mg	16,590 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until you heat it
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to licensed dispensary (Montgomery, Birmingham, or Tuscaloosa)	Ships directly to your Pickens County address
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC
Price range	$60-80 per 0.5g syringe	$129.99 for 30mL (16,590 mg total cannabinoids)

OilWell RSO vs. hemp CBD RSO products

Dimension	Typical hemp CBD RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15-50 mg	3,000 mg
CBN content	0-10 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa	Minimal	1,500 mg
Psychoactive option	No meaningful effect	Yes—via THCa decarboxylation
Price	$40-50	$129.99

Condition-specific usage context for Pickens County

Important disclaimer: The following usage contexts are informed by cannabinoid research cited below and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitutes for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

For cancer patients in Pickens County undergoing chemotherapy:

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence: delta-8 THC antiemetic [9], delta-9 THC nausea evidence [1][13], CBD anxiolytic buffering [3]

For chronic pain (fibromyalgia, arthritis, neuropathy)—common across Pickens County’s aging population:

• Daytime: 0.3-0.5 mL raw sublingual—provides anti-inflammatory exposure without impairment, allowing you to work, drive, or care for family
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

For sleep disorders:

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN—the dosage investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN—above threshold associated with reduced sleep disturbance
• Evidence: CBN sleep evidence [16][17], cannabis and sleep review [17]

For anxiety and stress—especially relevant for Pickens County’s veterans and healthcare workers:

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full profile including CBN for sleep architecture
• Evidence: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage evidence [20]

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility to Pickens County

We operate the only same-day RSO delivery system in Houston, but for Pickens County residents, we offer nationwide shipping that brings our products directly to your door.

Shipping to Alabama:

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for Alabama’s hot summers
• Signature-required option available

What you receive:

• Full documentation including Certificates of Analysis (COAs)
• Detailed usage instructions
• Legal compliance paperwork
• Receipts for your records

International shipping: We ship internationally and have delivered to multiple countries. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill.

For Pickens County residents, this means whether you’re in Aliceville, Carrollton, Gordo, Reform, or anywhere in between, you can access clinical-strength multi-cannabinoid RSO without leaving home. No 2-hour drive to Birmingham. No navigating Alabama’s restrictive medical cannabis program. Just legal, lab-tested, standardized product delivered to your door.

How our formulas connect to the evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section below. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

Our formulas are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging, and what is overstated. We do not exempt ourselves from the same evidence standards applied to the broader field.

OilWell Cannabis is more than a brand—it is a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. As we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that defined us from the day Bentley got up, walked across the room, and brought his ball to play.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving America’s fourth-largest city—featured Colin Valencia and OilWell Cannabis in seven distinct news segments. Five different reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

When ABC13 needed to explain a new cannabis product, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When President Biden announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and voice that anchored the report.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin as the most credible, quotable, and accessible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased—it can only be earned.

Complete ABC13 feature record

1. Texas CBD businesses booming—September 15, 2019

• Reporter: Tom Abrahams
• Colin’s foundational quote: “I’m not trying to sell people snake oil… there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot”

2. Entrepreneur creates direct-to-consumer business—March 22, 2021

• Reporter: Tom Abrahams
• Colin’s therapy quote: “Pain comes in a lot of different forms”

3. What is Delta 8 THC—May 24, 2021

• Reporter: Steve Campion
• Iconic exchange: “Maybe you want to get high”

4. Houston CBD shop giving away free products for COVID vaccine—August 20, 2021

• Company gave away 1,000 caviar pre-rolls (~$35,000 in product) to encourage vaccination
• Coordinated with city of Houston
• No political strings attached

5. Texas ban over once legal hemp product Delta 8—October 19, 2021

• Reporter: Shelley Childers
• Colin proactively removed all Delta-8 products before enforcement
• Warned other operators who were unknowingly shipping Schedule I narcotics

6. Biden marijuana pardon—October 7, 2022

• Reporter: Nick Natario
• Revealed Colin’s personal marijuana conviction history
• Introduced OilWell’s CBD vending machine
• Quote: “I would love to see people not get hurt for this anymore”

7. Marijuana industry getting creative—April 21, 2023

• Reporter: Nick Natario
• Colin’s “Renaissance” framing
• Featured him growing hemp on camera

Key facts from media record

• Seven features over four years (2019-2023)
• Five different reporters
• Topics: business, law, medicine, community health, politics, criminal justice reform
• Documented community action: $35,000 vaccine giveaway, proactive Delta-8 removal
• Personal stakes: revealed cannabis conviction history
• Evolution: from “local wholesaler” to industry authority

For Pickens County residents, this media record from a major Texas affiliate demonstrates credibility that transcends geography. When you’re considering a high-potency cannabis product, you want to know it comes from a company vetted by legitimate news organizations, not just marketing copy.

GENERAL KNOWLEDGE

Research method and evidence weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then preclinical literature when human data are sparse. This weighting matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still more dependent on reviews, animal work, and in vitro pharmacology [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite/weight-loss in HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis symptoms [1].
• FDA has not approved the cannabis plant for medical use, although purified CBD and synthetic THC analogues have specific approvals [1].
• Safety concerns include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination, and labeling inaccuracy [1].

Cannabinoid profiles

CBD

• Strongest human evidence in this formula set, especially as purified product [1]-[6]
• Best supported: seizure disorders [1][2]
• Anxiety: 2024 systematic review found significant anxiolytic signal but stressed limited clinical sample [3]
• Pain: 2024 review concluded promising but heterogeneous, with trial quality limiting confidence [4]
• Sleep: 2023 insomnia review found methodologically weak literature [5]
• Safety: 2023 review found real signal for liver enzyme elevation and possible drug-induced liver injury [6]. NCCIH flags diarrhea, sleepiness, appetite changes, mood effects, liver abnormalities, drug interactions [1]
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in few indications rather than broad wellness claims [1]-[6]

CBG

• Mostly review-level and preclinical; human evidence sparse [7][8]
• Pharmacology: biosynthetic precursor with distinct mechanisms including cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling [7]
• Potential areas: neurologic disorders, inflammatory bowel disease, antibacterial activity—but primarily pharmacology-led hypotheses [7][8]
• Caution: 2021 review notes CBG is sold commercially while evidence base remains thin [7]
• Bottom line: Promising minor cannabinoid with limited clinical validation [7][8]

Delta-8 THC

• Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11]
• Comparative pharmacology: 2022 review concluded broadly similar PK/PD to delta-9 THC, but less potent due to weaker CB1 affinity [9]
• Public health: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong human trials [10]
• Manufacturing: 2024 chemistry review notes commercial interest tied to stability and easier synthesis, with product-byproduct and lab-testing concerns [11]
• Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, manufacturing-quality uncertainty [9]-[11]

THCa

• Important chemically and formulation-wise, but low on direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC, may represent large share of THC-related content in raw plant material. Decarboxylates into THC during heating/storage [12]
• Psychoactivity: Does not produce psychoactive effects associated with THC if molecule stays acidic and isn’t substantially decarboxylated [12]
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities, but not established human outcomes [12]
• Bottom line: Highly relevant precursor whose interpretation depends heavily on route, temperature, processing, storage [12]

Delta-9 THC

• Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15]
• Institutionally best supported: NCCIH identifies relevance to chemotherapy nausea/vomiting, HIV/AIDS appetite/weight loss, some MS and pain outcomes [1]
• Pain evidence: 2022 systematic review found high-THC or comparable THC:CBD products may provide short-term pain benefit but increase dizziness, sedation, nausea, and discontinuation due to adverse events [13]
• Pharmacokinetics: Inhaled THC: effects within seconds-minutes, peak ~15-30 min, taper over few hours. Oral THC: later onset, later peak, longer duration [14]
• Mental health risk: 2025 systematic review found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety/depression in nontherapeutic settings [15]
• Broader safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency, withdrawal, pregnancy concerns, pediatric exposure, vape lung injury concerns [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15]

CBN

• Weak human evidence; marketing moved ahead of data [12][16][17]
• What it’s marketed for: Sleep/sedation. Reputation widespread, but clinical support far thinner [16][17]
• Sleep claim: 2021 narrative review screened 99 abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated review concluded cannabinoid sleep research still doesn’t match scale of real-world use, need for better-designed trials remains [17]
• Chemical context: THC can degrade toward CBN under certain conditions, explaining why CBN discussed in aging/oxidized cannabis contexts [12]
• Bottom line: Clearest example where cultural reputation stronger than current clinical evidence [16][17]

CBC

• Emerging, intriguing, overwhelmingly preclinical or review-based [18][19]
• Pharmacology: 2024 focused review argues distinct PK/PD and receptor behavior, highlights antinociceptive, antibacterial, anti-seizure as interesting targets [18]
• Older literature: Anti-inflammatory, reduced gut hypermobility, modest rodent analgesia, possible neurobiological/antiproliferative—but not strong patient-facing evidence [19]
• Safety caveat: 2024 CBC review notes over-the-counter CBC products sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19]

Terpene profiles

Limonene

• Mostly review and preclinical, with safety literature [20]-[22]
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities—but overwhelmingly from nonhuman/non-cannabis literature [21]
• Safety: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens [22]
• Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative [20]-[22]

Myrcene

• Mostly preclinical, very limited human evidence [20][23]
• Research: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, possible mechanisms, but explicitly states human studies lacking [23]
• Caution: Often invoked as proven sedating terpene explaining couch-lock—stronger claim than human evidence supports [20][23]
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive proof [23]

Caryophyllene

• Among most mechanistically interesting due to direct cannabinoid-system relevance, but mostly preclinical [24]
• Why it stands out: 2021 review describes beta-caryophyllene as selective CB2 receptor agonist—unusual and especially relevant pharmacologically rather than purely aromatic [24]
• Themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective—but human clinical confirmation limited [24]
• Bottom line: Arguably strongest candidate for terpene with cannabinoid-system significance, but should not be described as clinically proven [24]

Pinene

• Promising preclinical literature, weak human confirmation [20][25]
• Brain-health: 2021 review on pinene and linalool found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized lack of well-designed clinical trials [25]
• Caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC cognitive effects remain interesting hypotheses rather than settled facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25]

Linalool

• Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research: Repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 review found enough preclinical signal to justify continued investigation, but emphasized lack of robust human trials [25]
• Additional literature: Discusses possible antidepressant mechanisms, neuropharmacologic relevance—but translational rather than definitive clinical story [26]
• Safety: Oxidized linalool hydroperoxides are recognized allergens [22]
• Bottom line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Translationally interesting, but early [20][27]
• Scoping review: 2024 review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory/biologic effects, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, mood [27]
• Bottom line: One of more interesting terpene research targets, but far from clinically settled [27]

Terpinolene

• Least clinically characterized in this file [20][28]
• Systematic review: 2021 review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28]
• Caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20]
• Bottom line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28]

Research limits and interpretation

• Evidence base is highly uneven. CBD and delta-9 THC support most detailed human-facing statements; rest require more caution [1]-[29]
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable
• Minor cannabinoids and terpenes commercially interesting precisely because underexplored, but claims often become inflated
• Product quality matters as much as molecule identity—labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent PK all materially affect interpretation [1][10][11][14]
• For THCa, chemistry is destiny: storage and heating can change exposure profile by converting acidic cannabinoids into neutral cannabinoids like THC [12]

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid
  More accurate: Sleep evidence for CBN remains weak, no strong validated-trial base [16][17]
• Overstatement: Myrcene is proven human sedative explaining couch-lock
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof limited [20][23]
• Overstatement: Terpenes have proven entourage effects in patients
  More accurate: Entourage hypotheses influential and worth studying, but robust clinical proof limited [20][29]
• Overstatement: THCa is always nonpsychoactive
  More accurate: THCa itself not THC, but heating/processing can convert THCa to THC, changing effective exposure [12]
• Overstatement: Delta-8 THC is safe because hemp-derived
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, often entangled with manufacturing/testing concerns [9]-[11]

Practical takeaways for Pickens County buyers

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing; should not be interpreted same way in raw, gently handled, and heated formats
• CBG, CBN, CBC scientifically credible but clinically immature compared to CBD and THC
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5%
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

ORDERING INFORMATION FOR PICKENS COUNTY

How to order:

• Website: oilwellcbd.com
• Phone: (832) 416-2816
• Email: [email protected]
• Instagram: @oilwellcbd

Payment methods: All major credit cards, cryptocurrency options available

Shipping to Pickens County: 2-3 business days via USPS Priority Mail, fully tracked, discreet packaging

Returns: 30-day satisfaction guarantee on unopened products

Customer support: Real humans in Houston, not bots—available Monday-Thursday 10 AM-7 PM, Friday-Saturday 10 AM-10 PM, Sunday 10 AM-4 PM Central Time

FINAL THOUGHTS FOR PICKENS COUNTY

We know that Pickens County values self-reliance, community support, and honest dealing. We know that when someone in Aliceville is hurting, neighbors in Gordo care. We know that the opioid crisis has hit rural Alabama hard, and that many of you are searching for alternatives that actually work without the devastating side effects of pharmaceuticals.

Our story—from Bentley’s paralysis to Colin’s benzo withdrawal to the ABC13 newsroom—is not corporate mythology. It’s real. The formulas we publish are not trade secrets. They’re open-source recipes we hope will help you whether you buy from us or make your own.

The evidence we cite is not cherry-picked. It’s the actual scientific literature, with all its gaps and uncertainties laid bare.

We’re not here to sell snake oil. We’re here to give Pickens County—and everyone else—the best possible version of cannabis education so you can decide for yourself whether it’s right or wrong for you.

If you’re ready to try a product that puts control in your hands, that’s backed by real science, and that ships legally to your Pickens County door, we’re here.

If you just want the recipe to make it yourself, that’s here too.

Either way, we’re committed to one thing: not letting another person in Pickens County suffer needlessly because they didn’t have access to honest cannabis education.

LEGAL DISCLAIMERS FOR ALABAMA CUSTOMERS

• Age requirement: 21+ for all RSO products
• THC content: All products contain less than 0.3% delta-9 THC; Farm Bill compliant; hemp-derived cannabinoids
• FDA disclaimer: Not evaluated by FDA; not intended to diagnose, treat, cure, or prevent any disease; consult healthcare provider before use; individual results may vary
• Safety warnings: May cause drowsiness or impairment; do not operate vehicles or machinery; consult physician if pregnant or nursing; keep out of reach of children
• Alabama law: Buyer responsibility to verify local laws; OilWell assumes no legal responsibility for customer’s use or decarboxylation decisions; void where prohibited
• Medical advice: This information is educational only and does not constitute medical advice for Pickens County residents or any other location. Always consult qualified Alabama-licensed healthcare providers.

Alabama-specific considerations: While our products are federally legal, Alabama state law regarding hemp-derived products continues to evolve. We recommend Alabama customers retain COAs and purchase receipts. If you have concerns about workplace drug testing, be aware that decarboxylated THCa and delta-8 THC will trigger positive results. Raw THCa used sublingually without heating is less likely to trigger tests, but we cannot guarantee outcomes.

OilWell Cannabis—Houston-made, Alabama-legal, community-driven. Order today at oilwellcbd.com or call (832) 416-2816.